<li>aceclofenac<p>aceclofenac will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>acemetacin<p>acemetacin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>acyclovir<p>acyclovir will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>aluminum hydroxide<p>aluminum hydroxide will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>aminohippurate sodium<p>aminohippurate sodium will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>aspirin<p>aspirin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>aspirin rectal<p>aspirin rectal will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>astragalus<p>mycophenolate increases and astragalus decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>balsalazide<p>balsalazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>belatacept<p>belatacept increases levels of mycophenolate by Other (see comment). Use Caution/Monitor. 
Comment: Potential change of mycophenolic acid (MPA) exposure after crossover from cyclosporine to belatacept or from belatacept to cyclosporine in patients concomitantly receiving MMF.<span><br><br></span>belatacept and mycophenolate both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>bendroflumethiazide<p>bendroflumethiazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefadroxil<p>cefadroxil will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cefamandole<p>cefamandole will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cefpirome<p>cefpirome will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>ceftibuten<p>ceftibuten will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>ceftizoxime<p>ceftizoxime will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>celecoxib<p>celecoxib will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cephalexin<p>cephalexin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>chlorothiazide<p>chlorothiazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>chlorpropamide<p>chlorpropamide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>chlorthalidone<p>chlorthalidone will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cholera vaccine<p>mycophenolate decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clotrimazole<p>clotrimazole will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cyclopenthiazide<p>cyclopenthiazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>denosumab<p>mycophenolate, denosumab. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.</p></li><li>dexlansoprazole<p>dexlansoprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>dichlorphenamide<p>dichlorphenamide and mycophenolate both decrease  serum potassium. Use Caution/Monitor.<span><br><br></span>dichlorphenamide, mycophenolate.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.</p></li><li>diclofenac<p>diclofenac will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>dicloxacillin<p>dicloxacillin decreases levels of mycophenolate by decreasing metabolism. Use Caution/Monitor. decreases concentrations of active metabolite of mycophenolate possibly by reducing/impairing enterohepatic circulation.</p></li><li>didanosine<p>didanosine will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration</p></li><li>diflunisal<p>diflunisal will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>echinacea<p>mycophenolate increases and echinacea decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>esomeprazole<p>esomeprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>etoricoxib<p>etoricoxib will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>famotidine<p>famotidine will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>felodipine<p>felodipine will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>fenoprofen<p>fenoprofen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>fingolimod<p>mycophenolate increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .</p></li><li>flurbiprofen<p>flurbiprofen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ganciclovir<p>ganciclovir will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>hydrochlorothiazide<p>hydrochlorothiazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>hydroxyurea<p>hydroxyurea, mycophenolate. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of immunosuppression.</p></li><li>ibuprofen<p>ibuprofen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>indapamide<p>indapamide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>influenza virus vaccine quadrivalent, recombinant<p>mycophenolate decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>influenza virus vaccine trivalent, recombinant<p>mycophenolate decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>ketorolac<p>ketorolac will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>ketorolac intranasal<p>ketorolac intranasal will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>lansoprazole<p>lansoprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>levonorgestrel oral<p>mycophenolate decreases levels of levonorgestrel oral by unspecified interaction mechanism. Use Caution/Monitor. Consider additional birth control methods during mycophenolate administration.</p></li><li>loratadine<p>loratadine will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lornoxicam<p>lornoxicam will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>maitake<p>mycophenolate increases and maitake decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>mefenamic acid<p>mefenamic acid will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>meloxicam<p>meloxicam will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>meningococcal group b vaccine<p>mycophenolate decreases effects of meningococcal group b vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.</p></li><li>mercaptopurine<p>mercaptopurine and mycophenolate both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>mesalamine<p>mesalamine will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>methotrexate<p>mycophenolate, methotrexate.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Infections may occur.</p></li><li>methyclothiazide<p>methyclothiazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>metolazone<p>metolazone will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>midazolam<p>midazolam will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nabumetone<p>nabumetone will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>naproxen<p>naproxen will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>nefazodone<p>nefazodone will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nicardipine<p>nicardipine will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nizatidine<p>nizatidine will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ocrelizumab<p>mycophenolate and ocrelizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with high doses of corticosteroids is expected to increase the risk of immunosuppression.</p></li><li>omeprazole<p>omeprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>oxaprozin<p>oxaprozin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>pantoprazole<p>pantoprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Potential interaction applies to the prodrug mycophenolate mofetil conversion to active mycophenolic acid. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction.</p></li><li>parecoxib<p>parecoxib will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>piroxicam<p>piroxicam will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>probenecid<p>probenecid increases levels of mycophenolate by decreasing renal clearance. Use Caution/Monitor. Probenecid may interfere with renal tubular secretion of mycophenolate active metabolites.</p></li><li>quercetin<p>quercetin will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rabeprazole<p>rabeprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>reserpine<p>reserpine will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rose hips<p>rose hips will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>salsalate<p>salsalate will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>sipuleucel-t<p>mycophenolate decreases effects of sipuleucel-t by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.</p></li><li>sirolimus<p>sirolimus will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sodium bicarbonate<p>sodium bicarbonate will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>spironolactone<p>spironolactone will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sulfasalazine<p>sulfasalazine will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>sulindac<p>sulindac will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>tacrolimus<p>tacrolimus will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>telmisartan<p>telmisartan will decrease the level or effect of mycophenolate by  Other (see comment). Use Caution/Monitor. Concommitant administration with telmisartan may result in significant decrease in mycophenolic acid (MPA) concentrations; telmisartan changes MPA’s elimination by enhancing PPAR gamma (peroxisome proliferator-activated receptor gamma) expression, which in turn results in an enhanced UGT1A9 expression and activity </p></li><li>tolfenamic acid<p>tolfenamic acid will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>tolmetin<p>tolmetin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>tolvaptan<p>tolvaptan will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>trazodone<p>trazodone will decrease the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>valganciclovir<p>mycophenolate will increase the level or effect of valganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>verapamil<p>verapamil will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>willow bark<p>willow bark will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li>